Ask the Expert Webinar
Thursday, October 15, 2026
1 PM ET
Therapeutic peptides are a fast-growing pharmaceutical drug class, but they present unique analytical challenges due to closely related process impurities, degradation products, and higher-order aggregate species. This webinar shows how complementary chromatographic workflows can be used to address those challenges, with examples spanning assay, related substances, stability-indicating analysis, and aggregate assessment. Real-world applications will cover aggregation profiles of key GLP 1 receptor agonists including semaglutide, liraglutide, and tirzepatide.
As an attendee, you will learn more about:
- The main analytical challenges involved in therapeutic peptide characterization, including closely related impurities, degradation products, and aggregate species.
- Where reversed-phase chromatography and size exclusion chromatography fit across therapeutic peptide development workflows.
- How different reversed-phase selectivities were used for semaglutide assay, related substances, and stability/degradant studies, and understand how similar workflows can be adapted for other GLP-1 analogs, including tirzepatide.
